<SEC-DOCUMENT>0001055726-25-000064.txt : 20251110
<SEC-HEADER>0001055726-25-000064.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110160824
ACCESSION NUMBER:		0001055726-25-000064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		251466224

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ino-20251110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d6fe6ae4-16b5-4d2e-9f83-c047d5782d24,g:24222257-ecc5-4223-9447-7c936176f30e,d:796134a84a0b47819d22bde8da13420c-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20251110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20251110.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-10</xbrli:startDate><xbrli:endDate>2025-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i796134a84a0b47819d22bde8da13420c_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 10, 2025</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Inovio Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-14888</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">660 W. Germantown Pike</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 110</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">PA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">19462</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">267</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">440-4200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:2pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On November 10, 2025, Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93025x8kex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93025x8kex991.htm">Press Release, dated November 10, 2025 (filed herewith)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL).</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.935%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ino-93025x8kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if199ada5610343b3b96f74e50f55a561_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="picture3a.jpg" src="picture3a.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107&#59; requested priority review </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Commercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Results from Phase 1 proof-of-concept trial evaluating INOVIO&#8217;s next generation DNA-Encoded Monoclonal Antibody (DMAb</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">) technology published in Nature Medicine</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PLYMOUTH MEETING, PA &#8211; November 10, 2025 &#8211; INOVIO (NASDAQ&#58; INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2025 and provided an update on recent company developments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;I&#8217;m very pleased to report that we&#8217;ve completed the rolling submission of our BLA for lead candidate INO-3107. We believe every patient deserves a treatment that reduces exposure to surgery and INO-3107 has the potential to meet that significant need in the RRP community. The majority of patients in our Phase 1&#47;2 trial needed fewer surgeries after treatment and showed continued improvement through Year 2 without additional doses, and without surgical interventions during the treatment window to maintain minimal residual disease as required by other treatment modalities,&#8221; said Dr. Jacqueline Shea, INOVIO&#8217;s President and Chief Executive Officer. &#8220;As INOVIO works toward a potential approval for INO-3107 in mid-2026, we&#8217;re also working to advance our next generation DNA medicine candidates. Landmark proof-of-concept data on our DMAb technology was recently published in Nature Medicine and we are preparing for an upcoming presentation of promising pre-clinical data from our DNA-encoded protein technology (DPROT) at the World Federation of Hemophilia Global Forum. We look forward to sharing more on the company&#8217;s progress in the coming months.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Operational Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INO-3107 &#8211; Recurrent Respiratory Papillomatosis (RRP)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO completed the rolling submission of its BLA for DNA immunotherapy candidate INO-3107 for the treatment of RRP in adults. INOVIO submitted the BLA under the FDA&#8217;s accelerated approval program and has requested a priority review, which if granted, is expected to be completed within six months following file acceptance. Commercial preparations continue to advance for a potential launch in mid-2026. If approved, INO-3107 would be INOVIO&#8217;s first commercial product and the first DNA medicine available in the United States.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO plans to conduct a confirmatory trial and expects to begin enrolling patients during the BLA review period. The trial is expected to be conducted at approximately 20 sites across the United States.</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Peer-reviewed data from a retrospective study (RRP-002) investigating the long-term clinical and safety response of patients treated with INO-3107 were </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">published online in The Laryngoscope</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The data demonstrate that a majority of patients experienced continued improvement beyond the initial 12-month study period of the previously published Phase 1&#47;2 trial (RRP-001), as measured by the number of surgical procedures needed after treatment with INO-3107. Since our last report, INOVIO has also presented key data at several scientific conferences, including the American Academy of Otolaryngology &#8211; Head and Neck Surgery Annual Meeting, the European Society for Medical Oncology Annual Congress, and the 37th International Papillomavirus Society Conference. Highlights from the data include&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">81% (26&#47;32) of patients experienced a reduction of one or more surgeries at Year 1 post-treatment</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">By the end of Year 2, 91% (21&#47;23) of evaluable patients continued to experience a reduction of one or more surgeries. Only two patients had not yet responded to treatment with INO-3107</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">INO-3107 demonstrated continued clinical benefit, with a persistent decline in the mean number of surgeries through Year 2 post-therapy&#58; A 78% reduction in mean annual surgeries was seen at Year 2 compared to the 1 year pre-treatment period (0.9, n&#61;28 vs 4.1, n&#61;32)</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Clinical response was not dependent upon low viral loads, molecular subtype or other elements of the papilloma microenvironment </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Next Generation DNA Medicine Candidates</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Results from a Phase 1 proof-of-concept trial evaluating next generation DMAbs for COVID-19 were published online in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Nature</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Medicine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">demonstrating the technology&#8217;s potential as a long-acting, scalable and tolerable alternative to traditional monoclonal antibody therapies. Interim pharmacokinetic results were previously available as a preprint on Research Square. The study is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the Perelman School of Medicine at the University of Pennsylvania.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This was the first demonstration that monoclonal antibodies, complex proteins, can be durably and tolerably expressed in humans. INOVIO is building on this research to evaluate in vivo therapeutic protein production and will be presenting promising preclinical data from its DPROT program at the upcoming World Federation of Hemophilia Global Forum. This technology aims to address some of the shortcomings of conventional therapeutic protein replacement treatments including gene therapy approaches.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">General Corporate</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO remains focused on financial discipline and directing resources to advance the INO-3107 program towards commercialization and a potential launch date in mid-2026. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Third Quarter 2025 Financial Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Research and Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">R&#38;D expenses for the three months ended September 30, 2025, decreased to $13.3 million from $18.7 million for the same period in 2024. The decrease was primarily the result of lower drug manufacturing, clinical study and other expenses related to INO-3107 and lower expensed inventory, among other variances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">General and Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> G&#38;A expenses decreased to $7.9 million for the three months ended September 30, 2025, from $8.6 million for the same period in 2024. The decrease was primarily related to a decrease in employee and consultant compensation, including stock-based compensation, among other variances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Total Operating Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Total operating expenses decreased to $21.2 million for the three months ended September 30, 2025, from $27.3 million for the same period in 2024.</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Net Loss&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net loss for the three months ended September 30, 2025, increased to $45.5 million, or $0.87 per basic and diluted share, from a net loss of $25.2 million, or $0.89 per basic and diluted share, for the three months ended September 30, 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The increase in net loss for the period was primarily driven by a $22.5 million non-cash loss on fair value adjustment related to our warrant liabilities. As the fair value of the warrants fluctuates with our share price and other market inputs, this adjustment can result in significant variability in our reported net loss.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The loss from operations prior to other income (expenses) for the quarter ended September 30, 2025, was $21.2 million, or $0.41 per share, as compared with $27.3 million, or $0.97 per share, for the quarter ended September 30, 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Shares Outstanding&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of September 30, 2025, INOVIO had 53.6 million common shares outstanding and 94.5 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding common stock warrants, stock options, restricted stock units and convertible preferred stock.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Cash, Cash Equivalents and Short-term Investments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; As of September 30, 2025, cash, cash equivalents and short-term investments were $50.8 million, compared to $94.1 million as of December 31, 2024. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO&#8217;s balance sheet and statement of operations are provided below. Additional information is included in INOVIO&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2025, which can be accessed at&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;ir.inovio.com&#47;financials&#47;default.aspx</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Cash Guidance</font></div><div><font><br></font></div><div style="text-indent:-1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO estimates its current cash, cash equivalents and short-term investments balances will support the company&#8217;s operations into the second quarter of 2026. This projection includes an operational net cash burn estimate of approximately $22 million for the fourth quarter of 2025. These projections do not include any further capital-raising activities that INOVIO may undertake. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Conference Call &#47; Webcast Information</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO's management will host a live conference call and webcast with slides at 4&#58;30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">http&#58;&#47;&#47;ir.inovio.com&#47;events-and-presentations&#47;default.aspx.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About INOVIO's DNA Medicines Platform</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO&#8217;s DNA medicines platform has two innovative components&#58; precisely designed DNA plasmids, delivered by INOVIO&#8217;s proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. INOVIO&#8217;s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body&#8217;s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About INOVIO</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO&#8217;s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.inovio.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains certain forward-looking statements relating to our business, including the planned initiation and conduct of pre-clinical studies and clinical trials and the availability and timing of data from those studies and trials, the completion of the FDA-required device verification testing, the BLA submission and request for priority review and goal of FDA&#8217;s acceptance of the submission by the end of 2025, the potential commercial launch of INO-3107 if regulatory approval is obtained and timing thereof, the potential benefits of our product candidates, expectations regarding sufficiency of our cash resources into the second quarter of 2026 and expected cash burn for the fourth quarter of 2025. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Media&#58; Jennie Willson, (267) 429-8567, communications&#64;inovio.com</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Investors&#58; Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations&#64;inovio.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Inovio Pharmaceuticals, Inc.</font></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,567,420&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,813,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,235,770&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,300,232&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978,590&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199,056&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398,534&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,517,465&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,180,314&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,830,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,740,356&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,659,818&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,495,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,613,844&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,956,780&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,113,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012,476&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,979,654&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,385,656&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,197,206&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,323,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,200,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379,721&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351,163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">955,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,021,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,384,043&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,255,188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,738,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497,360&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,823,896&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,325,584&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281,737&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,367,827&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,105,633&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,693,411&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,572&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,099&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,811,803,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,799,362,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,818,930,043)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,730,219,262)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(647,356)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(675,667)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,719,977)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,503,795&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,385,656&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,197,206&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2025</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2025</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2024</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Revenues&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Revenue from collaborative arrangement </font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,343&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,762&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,333,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,733,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,945,638&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,734,891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,877,126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,613,895&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,465,208&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,395,232&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Total operating expenses</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,210,455&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,347,479&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,410,846&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,130,123&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Loss from operations</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,210,455)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,347,479)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69,345,503)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92,029,361)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Other income (expense)&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970,823&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,914,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177,833)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,515,730)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,680,868)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(589,618)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881,886&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136,061)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205,259&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330,811&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,810,868&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,938,236)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(579,819)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,641,901)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,254,466)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Net loss</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,496,672)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,165,478)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88,710,781)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87,872,447)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Net loss per share </font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.87)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.89)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average number of common shares used to compute net loss per share </font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,168,694&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,140,497&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,837,956&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,216,983&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20251110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d6fe6ae4-16b5-4d2e-9f83-c047d5782d24,g:24222257-ecc5-4223-9447-7c936176f30e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://inovio.com/20251110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inovio.com/20251110">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20251110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20251110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20251110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d6fe6ae4-16b5-4d2e-9f83-c047d5782d24,g:24222257-ecc5-4223-9447-7c936176f30e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f92135bf-4dfb-42db-9bd1-5dfdf8eeb84c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bb095403-ec00-4d0c-90cc-39251fb2a782_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_28b06e7b-93ee-4468-8213-d03e63e77484_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_00e4df74-89da-4a58-a8ee-2ffb839fe34d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cf8887ef-95ca-4620-9e73-4f9c199fbc38_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0c817599-1417-4e19-8987-8d4fef02cb8c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b871b799-2df0-4b4d-9dae-e8621ea1481d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_86dbf19c-d4a0-4e24-819d-a0201e993331_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_f91f4ade-a590-4144-a7d6-8c575192c465_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bde4fe26-9d05-42d4-931b-5c7221ad408c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5c923786-dc86-42dd-b8c2-8e351d064c8e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_cebc93f0-5ae0-43f9-80eb-eda1d7fedfc1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1fccc4b5-2a5a-4466-9580-8f07050a2926_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_300eb401-4399-4343-aef9-2786eeb494d6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3b251dfd-6df6-49d4-b30a-59d74200ec8e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4aa92ade-25dc-402c-b254-2a19f952779b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_10759775-db2e-480b-89a9-b316bc3530b9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0d9eadfb-cee2-45b4-858e-f4e250f98058_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1747b950-ee90-4671-85c9-d6e7c5e97516_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d62e4ef3-ed89-4d0f-a2c4-4ca6772d7ad2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_412d05ab-0c25-4f6d-a21e-87cdd2b6ab02_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c286488f-60d3-490d-a3a3-52ffd306a0e1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_11bbbd97-2337-4716-a917-4fd2066a2ca2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20251110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d6fe6ae4-16b5-4d2e-9f83-c047d5782d24,g:24222257-ecc5-4223-9447-7c936176f30e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20251110.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7b0b4225-7f0f-48be-8a85-5656a1f33615" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_DocumentType_7b0b4225-7f0f-48be-8a85-5656a1f33615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d6ea2254-c82d-4fb8-bd60-015c297a54d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_DocumentPeriodEndDate_d6ea2254-c82d-4fb8-bd60-015c297a54d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_711d3e1d-d031-4718-9d66-8f75d03252aa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityRegistrantName_711d3e1d-d031-4718-9d66-8f75d03252aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_42255af7-710a-4ac5-a5b9-3edf1a5a616a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityIncorporationStateCountryCode_42255af7-710a-4ac5-a5b9-3edf1a5a616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b17ed301-c212-49d5-945c-6e91d24f630d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityFileNumber_b17ed301-c212-49d5-945c-6e91d24f630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_77f6999c-8660-413b-8cca-36d25a1efcfc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityTaxIdentificationNumber_77f6999c-8660-413b-8cca-36d25a1efcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a9923c51-da03-4369-88e0-77a477e48ced" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityAddressAddressLine1_a9923c51-da03-4369-88e0-77a477e48ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6bcb9fca-4318-45a3-a298-2684f913b0d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityAddressAddressLine2_6bcb9fca-4318-45a3-a298-2684f913b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6cb72c57-a620-413d-982b-d0869676543c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityAddressCityOrTown_6cb72c57-a620-413d-982b-d0869676543c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_806c2854-52a0-4503-a4a3-9e9c074085ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityAddressStateOrProvince_806c2854-52a0-4503-a4a3-9e9c074085ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_86a0c80e-34d4-45e7-acfd-ce1d654e3ea5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityAddressPostalZipCode_86a0c80e-34d4-45e7-acfd-ce1d654e3ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4018aa91-37fa-42d5-acae-58382a9e986a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_CityAreaCode_4018aa91-37fa-42d5-acae-58382a9e986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e40c786e-2628-4a6e-ac93-8cf2443a0228" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_LocalPhoneNumber_e40c786e-2628-4a6e-ac93-8cf2443a0228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_76bfbe5f-2b92-4a85-a4ca-0cbf1de6d810" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_WrittenCommunications_76bfbe5f-2b92-4a85-a4ca-0cbf1de6d810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c857456a-88a4-4c92-9458-bf1ffd946e5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_SolicitingMaterial_c857456a-88a4-4c92-9458-bf1ffd946e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e2c09d65-71e2-4f35-bf52-3337eb8d4be6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_PreCommencementTenderOffer_e2c09d65-71e2-4f35-bf52-3337eb8d4be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d670d949-9188-46cc-8760-2116d8b185ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d670d949-9188-46cc-8760-2116d8b185ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6bdb9e59-ecf7-40dc-b160-1750cedd13c3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_Security12bTitle_6bdb9e59-ecf7-40dc-b160-1750cedd13c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_605ac3b1-3fa5-4a01-adec-fc19be22e680" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_TradingSymbol_605ac3b1-3fa5-4a01-adec-fc19be22e680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6c9ccf63-3659-4973-9bd1-2eb29e7095fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_SecurityExchangeName_6c9ccf63-3659-4973-9bd1-2eb29e7095fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_777cefca-df99-4381-aef8-7e2b5d8752c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityEmergingGrowthCompany_777cefca-df99-4381-aef8-7e2b5d8752c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8920a4b5-614f-4d76-a372-29bdc9fd4be9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_EntityCentralIndexKey_8920a4b5-614f-4d76-a372-29bdc9fd4be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4fc06750-cbaa-49eb-9d1a-f4e244db9cea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b6466c0-8cb6-4ef2-8f90-a050dff6b743" xlink:to="loc_dei_AmendmentFlag_4fc06750-cbaa-49eb-9d1a-f4e244db9cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>picture3a.jpg
<TEXT>
begin 644 picture3a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ K8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBDH 6BDI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFO(
ML:,[L$11DLQP /6@!U%9B^*-&D9575K%F8X %RA)_6M.@ HHHH **I7FMZ=I
MTHBN[^UM92-P2:94./7!--M=>TR^G$-MJ-I<3,"1'%.K,0.IP#0!?HI*6@ H
MHHH **** "BBB@ HHHH ***@O+ZWT^'SKJXBMHLX\R9PBY/09- $]%4;37=-
MU"80VNH6MS+C/EPSJ[8'4X!J]0 4444 %%)1F@!:*3-&X>M "TU^U!85R'Q%
M^(^E_#O25N[]O-GD.(;6(@R2GV]!ZDUG4J1IP<YNR1$YQA%RD[(ZUFV]\4#G
MFOG?PK\6O'OQ/UZ>U\/IIFF00H&E^U(9"BDD!NH)/'05K^+_ !K\1/A?9QZG
MK+Z-K>GR,(2+='@*2'IUR2.#7FQS"E4I^V2?+WL<D<7"4/:).W<]RXI5KS3X
M;?&?1?'[?9$9['4MNXVLY&2.F4/1O7'7FO2(N,UW4:U.O'GINYT4ZL:L>:+)
M:*3(HW#UKH-A:*3(]:6@ HHJM?:G9Z:J->7<%HKG"F>14!/H,F@"S15&SUS3
M=0F\JUU"UN9<;O+AF5VP.IP#5Z@ HHHH **** "BBB@ HHHH **** "BBH;J
M\@L83-<SQV\0X,DKA5'XF@":BLV'Q)I%Q*D46JV4DDAVHB7"$L?0#/)K2H *
M*ANKR"QA,US/';PKUDE<*H_$U4@\1:3=3)%#J=G+*YPL<=PC,Q]  >: -&BB
MB@ HHHH ***2@!:*3-0WE[;Z?"9KJ>.VA'!DE<(N3[F@">BO+/$W[2OPX\+?
M:%NO%%K<3P/LDM[+,\@.<=%%<+KG[<7@33TC_LVTU;6&;[P6#R-OXN1F@#Z-
MHKY:_P"&]_#8_P"95UC_ +^P_P#Q56=-_;M\(W-Y%'>:'K%A Q^:<^7)M_X"
MIR: /IRBO&-$_:W^&.N7+PG7FTW"[O,U&V>!#]&(KTW0?%6C^*K6.YTC5+34
MX73>IMIE?*^N <X^M &U124M !1110 4444 %%%% !1110 4444 %%%% !11
M10 5@^/>? OB('_H&W/_ **:MZL+QY_R(WB+_L'7'_HIJ /RN\%V\7_"2>'_
M -VG_'[;?PC_ )Z+7ZUQ_P"K7Z"OR8\%_P#(R>'_ /K]MO\ T8M?K/'_ *M?
MH* 'T444 ?!7[=44<GQBTXNBM_Q)H>6 _P">LU>"^']6OO"NM6FKZ1.]AJ5K
M()8;B+Y2#[GN".".G->^?MT?\E@T[K_R!H>AQ_RUFKSC0/@WJGBKX4ZAXRTA
M6OGTV\:&[LHT^80A0WFH.^.XZXY[4 ?=WP/^,VF?&+PO%>VK+;ZK;A8]1L&X
M:&3'4#NC=5/]:]+R/6ORS^%?Q.U3X3^+K77=)VS!1Y=S;-PEQ"3RI]#W!'?%
M?I1X"\::;\0O"^GZ_I$IEL;M-PW$;HVZ%&'8@\4 =+129I: "BBB@ HHHH *
M*** "O _VVE5_@7<!@&']H6O!'^W7OE>"?ML?\D+N/\ L(6O_H= 'SC^Q3$B
M?'>V*HJG^S;KD#_<K]":_/G]BO\ Y+M;?]@VZ_\ 9*_0:@ IK4ZD:@!AIDS*
MD)8L$5>2S'@#U-+)D+TSS7SQ\8OB)#K'CBT\(W&H-I^@1RQ_VG-'D>9D@["P
MZ)C&?<G/2N/$XF.&BI3W9S5JT:$5*74ZSQ?^T-HGAN2:.QMKG7'AD,<LUNN(
M$?ICS#P>>,"N)/[4FM*J7$WAB%+%C_KA(^,9[,1M_7K7M=YX-T?4/",VAQ6L
M":;<0>4JP *H!'RLI'X$'VKQ[X,ZDWA3Q'J/P\\1Q),HE:2T\Y,H3C)QN[,,
M$>^17BXF6+C6BO:\L9=EU['G5GB/:1_>63\NIU?A?]H[POKJF*\\[2;CDA+C
M#*PQD?..,GTKROPKIMQ\=OBM>7VHL[:5;GS2FXX6('$<8ST#8R>_-=;^T%\-
M_#6B>&VUJPLEL-0:9%'D-M63<WS$KT) KSKX4_$VY^%]]BZL6ETO4-LK87$F
M!QO0_P 0]J\K$XBK[>&'Q;]U:Z=?4XZU6?MHT<0[I=OU/1OA-);Z'\=O%^D1
MPB.*8,L048"!"#CZ?-6G^U7J"P>#M.LV_P!9<7.\8_V%.?\ T(?G6!X0U'39
M_P!HQ]1T^Z6XL]2LVG1QW9U4D>WW>E:O[3$EM>ZIX.L)G7Y[LF52<8C8JI)]
MNM=G-!8"I"#T3:^]F]X_59Q3TO\ J9'Q:^$K:3IEMXP\.9LYK>*.6YBB^4KA
M1^\3'0CN/QK?\._M*Z3!X/MKC5P\FN*#&]K:Q_ZPCHP)X 8?J".U9?Q6^/%M
M:V,WA[PV4NF:+R);T#=''D;2J#^)L?A7E_PK\.V&I?$*QTG7[24QR[@D,A*#
M>!N&_P!B >/<5P3Q7L,2H8'KH^USEE75&ORX?KOVN>L6/[0WB;Q-?.OA[P=]
MLMNH:21L@9P26 V]?2M3P7\>[[Q!)J(O/#[R0Z><W%SI;F=(UY^;:<%NF>.W
M-6/CCXNA\#^%8/#^BPQP7^IYACBMU \N/HQ '0G.T>Y)[5TOPA\ +X#\(P6T
MHS?W!$UTPY^<@87/HH 'X$]Z]JE]9>(]FJE[;Z*R[)'HP]M[7EY[VW.OT75K
M/6K%+RPN([JWDZ/&<CZ>Q]C6BO>OG?Q#\0-.^&_QA<:9=M-IM[A=7LH5S'',
M>!(O^UTW >GJ:^@[2020AP00PR"#D'WKUL/B8UW**>L79G?2K1J-QOJMR>O&
M?VK/ADOQ)^%=YY-NLVJ:3F_M,C).T?.@]-RY_*O9JBF7>NTKN5@05(R#7<=)
M^4_PW\72_#SQKHWB.S7#64RNX4<O&>'3CKE<\'OCTK]3M$U6VUS2;74+259K
M6ZB6:*13D,K $<_C7YM?M!?#S_A6?Q4U?3(8V33[A_MMF6R1Y<AR5R>NTD@^
MG%?4/[%/Q$/B3P%/X9NI-U[H+@0Y)):V<DI^"G<N/0#UH ^DZ*:N=O/6G4 %
M%%% !1110 4444 %%%% "5\;_MV?$475YI7@>UD5DB'V^^4<_.01$A]" 6;!
M_O*:^M/$6LVWAO2;_5KYC'96-N]Q,PY.U02<#N>,8K\M/''BZ\\>>+M5\0WW
M-QJ%P9=FXD(I.$0$] %P!]* /7_V-/AC#XN^)C:Y<6R/I^@(LZDH"#<L2(OQ
M&&?([H*^_P"/_5K]*\I_9O\ AN?AG\*M+L[B(KJM\/MU[D8(DD PI_W5"@CU
M!/>O5USM&>M 'BW[8BA_@+K@8!AYMOP1_P!-5KXL_9ZAC7XX^"2(U!_M).0!
M_=:OM3]L+_D@VM_]=;?_ -&K7Q=^SW_R7#P3_P!A)/\ T%J /TZHHHH ***3
M- !63K_B#3?"NFW&HZK>P:?8Q M)<7+A5'!/YX'0<USOQ4^*6B_"3PW)K&M3
M'YF*6UG&1YMU)V51_,] *_//XJ?&+Q%\6]6:]UR[VV4;E[73HSB"VSQT[G'&
M3R: /H'XG_MQ.SR67@33@%#;?[5U&,G/3[D6?]X?-]17S3XB\;>*/B)?;=6U
M?4==N9<;8&=G# =,1J,''^[7L?P9_9 U[QU'#JGB8S>'-%8@I R_Z5.I7((!
MX09QRW/7I7V#X$^$OA3X:VJP>'M%@M).K73KOG<CC+.>>] 'P=X5_9=^(_BR
M'S;;PZVG0;5=)-3E6 .K#@J.2>/85Z19_L&>)Y(87N?$VEVSMAI(EAD<H>X#
M=#7V\.@I: /DBW_8#LOLX\_QC=";N([1-GZG-8>H?L#ZRMP1I_BRQ-OV^TVK
M[O\ QTXK[3HH _/7Q-^QO\1O#_VF2TM+/6[>$95K.<+))SU6-N?PS7E-]I/B
M/X=ZLRW-MJ7AO44;8S$/;N3P<!APPZ< D<5^L%96N>'--\2:>]EJMA;ZC:2*
M5:&YC#C!&#UZ<>E 'PS\.?VS/&'A5XK?Q$J^*-.!RTDN$NE!.20XX8]@"!7U
M[\,?C%X7^+&GF?0+]9;F,*T]C-\D\.<]5[C(/(XKPOXM_L2V-_YVH> Y_P"S
M[HG<=)NFS Q).=CGE, C@Y''O7RBR^(?AOXI <7N@:]82 CK'(C*W'L5X]P<
M4 ?J_FEKYX_9[_:AM?BA-#H/B#R=/\4;?W3+\L5Z ,G;_=?&3M[]J^ALB@!:
M*** "BBB@ HHHH **** "BBB@ HHHH *PO'G_(C>(O\ L'7'_HIJW:PO'G_(
MC>(O^P=<?^BFH _++P7_ ,C)X?\ ^OVV_P#1BU^L\?\ JU^@K\F/!?\ R,GA
M_P#Z_;;_ -&+7ZSQ_P"K7Z"@!]%%% 'P9^W1_P EAT[_ + T/_HV:O6OV$@&
M^&>N C(.I,"#_N+7DO[='_)8=._[ T/_ *-FKUO]A'_DFNM_]A-O_0%H \<_
M:H_9_/PTU5_$NBH7\-:A,?,AQS9S-_#_ +C'IZ'CTKF_V<_CE<?![Q6L=Y/(
M_A>^?;>P ;O*/03*.Q'?'45^A.O:#8^)M)N],U6TCO;"ZC,4\$@RKJ?ZCK7Y
MQ?';X-WOP;\826FR6;0[IB^G7L@R)$Z[&;^^O<=QS0!^DFE:A;:O9V]_9W$=
MU:W""2&:%MRNA&00:O9'K7P]^R3^T(WA6\M_!&O29T:ZDVZ?=N<?992?]6W^
MP3T/8_6OMR/[PSU_SQ0!-1110 4444 %%%% !7@G[;'_ "0NX_["%K_Z'7O=
M>"?ML?\ )"[C_L(6O_H= 'SI^Q7_ ,EVMO\ L&W7_LE?H-7Y\_L5_P#)=K;_
M +!MU_[)7Z#4 %-=MHI=P]:@O+B*VMWFFE2**,%WD=@JJHY))["C?03=E=BL
MW4CI7RCX.\(V'Q*\=>-K*[!2XD,TUK*3DQ,)NOZ@?3->@>-/VQ?A?X)N9;>3
M7_[6N8F,<EOI41G8<=<\*1[@FOG+P;^U5X0\)_%74->4:F='O))]ZK9CS/+9
MBR@+NXPVW\JY\;D6.QLJ4HT9.-^Q\MC\RP7/",ZBWUU/>_A'\0+KP'K#>!?%
M@-J\3[+.YE/RX)X7)_A/\)_"M3]H;P7,UI;>,=,/EZCI15I&48)C!R'S_L')
M^A->/_%/]J#X1_$C0S_I&I0:M ,VL[6/.3_"WS?=/Z=16;X9_;;5O!O_  C-
MAX;U+Q9XE=3#:0^3D21[2 7 R3MXSZCG(H609C[-X>K3?+TD^AE_:>$<7A^>
M_9HZKXF?$2;XMQ^%=)TZ'==L%,\(7I<M\H /L,MCW%>[77P@T/5O!6G^'KZV
M\Q;&%4BN$)\Q&QRRM]2:X/\ 9W^!M]X3@3Q-XN$4OBBX4F*R@_U&F1L.47^]
M(>[?@..OO42E>H.?>N"EEW)*3Q#4I/3Y(]?!T95(NK77O2_(^;_^&>?$WA#7
M+?5?#6HVMY-;S;XTN@8SMQ@[CR#WZ"F>)/@W\1/B!K%O<Z_+ID"QH85DA?.Q
M"2<8 R>:^ECGM30IK+^R,/R\JOR]C7ZA1Y>76WX'DOP[_9\TCP;/%?WS?VOJ
MB<JSKB*,^JKZ\=3ZUYK\>=-E\&_%+3?$:(98KAHIUW8 +Q$ H/; 4D^]?4N>
M<8.:YGXA>!+/X@>'I=.NQY4GWX+A5!:)QT8?R_&IQ66P>&=/#KE:U0J^#BZ7
M)25FM5ZGC'PITJZ^+'Q%O?&FJQL;"SD"VD; 8W#E5_X #D^Y!KL/C1\6CX3M
M1H6D,TWB&\ 15AY: -QG']X] .O?Z^<77Q0\0?L_V,?A#4O#\:Q,LIM-?6<)
M;LS$D AAR^2>,YP#Z<^;?#O]I'X;^"_$%[K'B6;5]9\0^:P$T-H)HT/=E8MR
MQ]>PX%5A,OQE>"H8:#E.2NY+H>/+'4L,O8SERR?Q-G6_$'X7OX'^'^EWNH#?
MKFH7F;AF;)C!1CLSZYP2?7Z5](_";6#KOP\T*\9?+9K94*YS]S*9S[[:^7OB
MA\=M#^-=CIUUX=.H1Z?9F42+?0>5F3 P5&3G W?G79?#?]M+X4V^C:;HLE]=
MZ/\ 9;9$:>\M&2$L -VTJ6)R<]N]5EV65XXVM&C!V@DGZ^88;&X2CB)*-1*-
MEOU/I_<#WS3EK'\-^)M)\5:7%J&D:E;ZE92\I/;RAU/&<9!X/J#R*V%KVFG%
MV>A]5&2FN:+NCYS_ &U_AJ/$W@&'Q/:Q@ZAH3;I2!R]LYPX]3M." />OE7X!
M_$5OAC\3])U9Y/+TZ5OLE\&/'DR$ L?3:=K9] 1WK]*]7TVWUC3KJQND$EK=
M1-#*A.-R,"",_0U^6OQ&\$W'P]\<:SX=NQEK.=EC=E($D1Y1AR3@J1^5!1^J
M5NP>/>K;E;D-ZC%2UXW^RK\23\0OA39+=3>;JFDG[#=%CEFV@;)#D\[D*DGI
MG([5[)0 4444 %%%% !1110 4F<=>*6J]U(L*M)(XBB4%G=F "@#DD]OK0!\
MU_MP?$8:'X/M/"-K+B[UIA+<;3RENAR 1_M.!@C^X?6OG/\ 9M^&Y^)?Q6TV
MVEBW:98G[?>97(:-",(<\$,VT$=<%O2L;XW?$*3XG?$S6=;#LUGYGV>R5LC;
M GRIQDX)QDXXR37U]^QQ\.6\'_#+^VKF'9J'B!A=99?F$ !$0/)!R"7'^_[4
M ?0$2[8P.M/IJ_=%.H \6_;"_P"2#:W_ -=;?_T:M?%W[/?_ "7#P3_V$D_]
M!:OM']L+_D@VM_\ 76W_ /1JU\7?L]_\EP\$_P#823_T%J /TZHHHH *YKQY
MXTTWX?>&=0U[5YU@L[1"_)P9&Q\J+ZLQX'Y]JZ3/;O7P9^V/\7'\8>-F\)V,
MQ.C:+)B8*>)KK^(GC^ ?*/?)[T >3?%#XF:U\7/%DVM:L[,Y/EVEG'DI;1Y^
M6-!ZGN>I-?5G[-_[+-KX;L[7Q-XPLUNM;D EM=/E&Z.S'9F'1I#Q[#I7"?L=
M? Z+Q-?'QQKMJLVG6<GEZ;"YRLDP/S2D=PG09_BS_=K[;7.T9ZT "_=%+110
M 4444 %%%% !1110 5YA\;/@AI'QGT#[-=*MEK-N"UEJ:)EHF/\ "W]Y#W';
MJ.17I]% 'Y0^*?"VN?#7Q9/I.J12:9K%A(&5HVQGG*RHW\0.,@CW[C%?>'[,
MOQRB^+7ADV5^WE^)M+11>;N/M"]!,OUX!'8_6I/VF/@HOQ9\&M/8Q!?$FEH\
MUFZJ,S+_ !0$^C8R/0X]Z^%/AWXXU+X7>-M/UZR#1SV<FV>W<,OF1YQ)&PZ]
M,C'J* /U4W#UI:R/#NMV?BC0]/U?3W6:SO85GAD4C[K#.#@]1T/N#6O0 444
M4 %%%% !1110 4444 %%%% !6%X\_P"1&\1?]@ZX_P#135NUA>//^1&\1?\
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MVTDN[/@\[KQKXF&"J-\BU=MWV1K_ !8_8U\6_"!8?$W@+5KW5Q:!2ZVN8[Z
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M&K7Q=^SW_P EP\$_]A)/_06K[1_;"_Y(-K?_ %UM_P#T:M?%W[/?_)</!/\
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M&/[P&/2O>_M"IAZDL*I\L):P:T2[7\N_F?._4(8BC'%.+E.%U-/KW_X!\O\
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MIW_8&A_]&S5ZY^P?_P DUUO_ +";?^@+7D'[=4T:_&'3MTBK_P 2:'[S ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ino-20251110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ino-20251110.htm">ino-20251110.htm</File>
    <File>ino-20251110.xsd</File>
    <File>ino-20251110_lab.xml</File>
    <File>ino-20251110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20251110.htm": {
   "nsprefix": "ino",
   "nsuri": "http://inovio.com/20251110",
   "dts": {
    "inline": {
     "local": [
      "ino-20251110.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20251110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20251110_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://inovio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20251110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20251110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001055726-25-000064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-25-000064-xbrl.zip
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M?U*V7]%Q*UX MI616)2!4J9>*&AZM50M5LU[A>"PS>O6/+4BWI&RD)B#\N6
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MR?+X^9[O3.#/0 [=^O\!4$L#!!0    (  N!:EM#-%"&7 (  .0&   0
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M[B#O$"FI:%M=SMN7=9;6&7W;NJ6*#K=J]_]J\YQAM\[3WA]02P,$%     @
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M7,=3ULZ$MY1:*S+N0HZ4FBVT,Z4=S)2NGX-AF05*3S 0,.$4LN\,K9!E2JN
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M!0X>+'32^5<4]D!Z.)U.&S<4@8U%EJX+(T1=&IOV(7)^9[=MC0Q"N=S/FM^
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M<QQG*T_YE6@,8\&_-/@(CG',@QL^4_./GP#)S6]]U487R7\U5-:&Z*-;9NZ
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M;F\M,C R-3$Q,3 N:'1M4$L! A0#%     @ "X%J6T,T4(9< @  Y 8  !
M             ( !X0\  &EN;RTR,#(U,3$Q,"YX<V102P$"% ,4    "  +
M@6I;W0["+E8*   &6   %               @ %K$@  :6YO+3(P,C4Q,3$P
M7VQA8BYX;6Q02P$"% ,4    "  +@6I;QQ)*J=4&  #K,@  %
M    @ 'S'   :6YO+3(P,C4Q,3$P7W!R92YX;6Q02P$"% ,4    "  +@6I;
M"UME1;,F  !*JP$ %0              @ 'Z(P  :6YO+3DS,#(U>#AK97@Y
<.3$N:'1M4$L%!@     %  4 0P$  .!*      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ino-20251110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20251110.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001055726</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
